Semaglutide (Novo Nordisk)

在2次倍受业内关注的离职后，兜兜转转，石药原执行总裁刘勇军回到了自己原先创立的药企，担任董事长一职，领导科学创始人团队。 近期 ，药研网通过企查查查询发现，石药原执行总裁刘勇军目前担任华普生物董事长。 2024年8月，刘勇军离开信达生物，随后，9月5日，石药集团宣布聘任刘勇军为集团执行总裁、全球研发总裁，但履新不到三月后，刘勇军再次离任。 华普生物官网显示，刘勇军为其科学创始人之一。 华普生物成立于2001年，围绕TLR9的激动剂—CpG开发具有全球知识产权的疫苗佐剂和肿瘤治疗产品，是具有CpG核心专利和迭代开发能力的新药创制公司，已完成工艺放大及规模生产的建设，目前在TLR9激动剂CpG领域处于全球领跑地位，产品授权业界多家企业进行开发。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。 转载/商务/投稿 | 联系微信15618157102（sum_Gmi） 商务合作 稿件征集 点击了解详情 往期回顾 1 12月 | 16家生物医药裁员汇总 2 全球第一款司美格鲁肽咀嚼软糖上市！ 3 中国首个男性HPV疫苗获批上市!

The U.S. government announced on Friday that 15 medications, including Wegovy for weight loss and Ozempic for diabetes, will be part of the Medicare price negotiation plan set to take effect in 2027. This initiative stems from the Inflation Reduction Act signed by the Biden administration in 2022 and aims to reduce Medicare's spending on expensive drugs. Key Medications Involved Among the 15 drugs targeted for negotiation are: Ibrance and Xtandi (cancer treatments from Pfizer) Trelegy Ellipta (treatment for asthma and COPD from GlaxoSmithKline) Austedo (for Huntington’s disease from Teva) Linzess (for irritable bowel syndrome from AbbVie) These medications are among the highest expenditures for Medicare, particularly for individuals aged 65 and older or those with disabilities. President Biden emphasized that these 15 drugs, alongside 10 others negotiated last year, account for nearly one-third of Medicare Part D prescription drug spending. Negotiation Participation and Penalties Pharmaceutical manufacturers must decide by February 28 whether to participate in the negotiations. Those opting out may face penalties of up to 95% of their drug sales or be required to withdraw their products from Medicare and Medicaid. Historical data suggests that the price reductions implemented in 2026 could range from 38% to 79%, significantly reducing Medicare's drug expenditure. For instance, Wegovy costs approximately $1,350 per month, while Ozempic is about $935. Despite Novo Nordisk's claims of offering discounts, Medicare's spending on these drugs exceeded $4.6 billion in 2022. Financial Implications Government researchers warn that if Ozempic and Wegovy are used at their current prices, they could contribute to an increase in the U.S. deficit over the next decade. By October 2024, around 2.3 million Medicare Part D beneficiaries were reported to be using Novo Nordisk’s semaglutide drugs, leading to total expenditures of over $14 billion for Medicare Part D. Future Considerations It remains uncertain whether a future Trump administration would alter the negotiation process. However, Biden administration officials have indicated that any successor might find it challenging to change the negotiation framework, as the law outlines specific criteria for participation.   The inclusion of these 15 high-cost drugs in Medicare's price negotiation plan represents a significant step toward controlling pharmaceutical costs in the U.S. As negotiations commence, the outcomes could reshape the landscape of drug pricing and accessibility for millions of Americans.